Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Ministry Recommends Approval For J&J, GSK Drugs; Takeda Actos/Alogliptin Combo Missing

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare has recommended 10 drugs for marketing approval; these include new drugs from Johnson & Johnson, Eli Lilly, GlaxoSmithKline and Nippon Medi-Physics
Advertisement

Related Content

Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
Pfizer Banking On China's Emerging Neuropathic Pain Market For Lyrica
Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
Advertisement
UsernamePublicRestriction

Register

SC075797

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel